South Dakota § 34-20B-25 - Substances included in Schedule IV.

§ 34-20B-25. Substances included in Schedule IV.

The following are included in Schedule IV:

(1)    Chlordiazepoxide, but not including librax (chlordiazepoxide hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and water soluble esterified estrogens);

(2)    Clonazepam;

(3)    Clorazepate;

(4)    Diazepam;

(5)    Flunitrazepam;

(6)    Flurazepam;

(7)    Mebutamate;

(8)    Oxazepam;

(9)    Prazepam;

(10)    Lorazepam;

(11)    Triazolam;

(12)    Any substance that contains any quantity of a benzodiazepine, or salt of benzodiazepine, except substances that are specifically listed in other schedules;

(13)    Alprazolam;

(14)    Midazolam;

(15)    Temazepam;

(16)    Cathine;

(17)    Fencamfamine;

(18)    Fenproporex;

(19)    Mefenorex;

(20)    Pyrovalerone;

(21)    Propoxyphene;

(22)    Pentazocine;

(23)    Diethylpropion;

(24)    Ethchlorvynol;

(25)    Ethinamate;

(26)    Mazindol;

(27)    Mephobarbital;

(28)    Methohexitol;

(29)    Paraldehyde;

(30)    Pemoline;

(31)    Petrichloral;

(32)    Phentermine;

(33)    Barbital;

(34)    Phenobarbital;

(35)    Meprobamate;

(36)    Zolpidem;

(37)    Butorphanol;

(38)    Modafinil, including its salts, isomers, and salts of isomers;

(39)    Sibutramine;

(40)    Zaleplon;

(41)    Dichloralphenazone;

(42)    Zopiclone, also known as eszopiclone, including its salts, isomers, and salts of isomers;

(43)    Pregabalin;

(44)    Lacosamide;

(45)    Fospropofol, including its salts, isomers, and salts of isomers;

(46)    Clobazam;

(47)    Carisoprodol, including its salts, isomers, and salts of isomers;

(48)    Ezogabine,[-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester], including its salts, isomers, and salts of isomers;

(49)    Lorcaserin, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible;

(50)    Alfaxalone, 5[alpha]-pregnan-3[alpha]-ol-11,20-dione, including its salts, isomers, and salts of isomers;

(51)    Tramadol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers;

(52)    Suvorexant, including its salts, isomers, and salts of isomers;

(53)    Eluxadoline,(5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) including its optical isomers and its salts, isomers, and salts of isomers;

(54)    Brivaracetam;

(55)    Solriamfetol (2-amino-3-phenylpropyl carbamate; benzenepropanol, beta-amino-, carbamate (ester)), including its salts, isomers, and salts of isomers whenever the existence of the salts, isomers, and salts of isomers is possible;

(56)    Brexanolone, (3[alpha]-hydroxy-5[alpha]-pregnan-20-one), including its salts, isomers, and salts of isomers whenever the existence of the salts, isomers, and salts of isomers is possible;

(57)    Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester);

(58)    Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl)-benzamide];

(59)    Lemborexant, including its salts, isomers, and salts of isomers;

(60)    Remimazolam;

(61)    Serdexmethylphenidate, including its salts, isomers, and salts of isomers;

(62)    Daridorexant, including its salts, isomers, and salts of isomers;

(63)    Ganaxolone, including its salts;

(64)    Zuranolone; and

(65)    The pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the United States Food and Drug Administration.

Source: SL 1977, ch 315, § 6; SL 1978, ch 249, §§ 2, 3; SL 1980, ch 240, § 2; SL 1981, ch 261, § 3; SL 1985, ch 278, § 53; SL 1987, ch 255; SL 1989, ch 293, § 4; SL 1990, ch 270, § 2; SL 1992, ch 245, § 3; SL 1993, ch 247, § 7; SL 1994, ch 278, § 4; SL 1995, ch 191, § 2; SL 1999, ch 174, § 2; SL 2000, ch 170, § 4; SL 2002, ch 167, § 2; SL 2003, ch 183, § 4; SL 2006, ch 179, § 2, eff. Feb. 9, 2006; SL 2010, ch 174, § 3, eff. Feb. 24, 2010; SL 2012, ch 183, § 3, eff. Feb. 23, 2012; SL 2013, ch 156, § 5, eff. Mar. 6, 2013; SL 2015, ch 180, § 5, eff. Feb. 18, 2015; SL 2016, ch 175, § 4, eff. Feb. 18, 2016; SL 2017, ch 156, § 3, eff. Feb. 3, 2017; SL 2017, ch 155, § 2; SL 2019, ch 148, § 4, eff. Feb. 19, 2019; SL 2020, ch 144, § 3, eff. Mar. 9, 2020; SL 2021, ch 144, § 6, eff. Feb. 17, 2021; SL 2022, ch 109, § 4, eff. Feb. 9, 2022; SL 2023, ch 119, § 3, eff. Feb. 9, 2023; SL 2024, ch 130, § 3, eff. Feb. 14, 2024; SL 2026, ch 149, § 2.